Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Where next for Bovis after marriage proposals?

Don’t be tempted to chase Bovis Homes (BVS) shares higher after a surge on takeover interest (13 Mar) to 900p. For the really big housebuilders, organic expansion through land acquisition is already delivering strong returns and this removes the rationale for any deal.
Unsolicited merger offers from mid-cap operators Galliford Try (GFRD) and Redrow (RDW) have both been rejected by the board of embattled Bovis.
Galliford Try proposed an all share merger that would split the combined entity 52.25% to Galliford Try shareholders and 47.75% to Bovis shareholders, implying a valuation of 0.56 Galliford shares for each Bovis share.
UBS calculates that, as of 10 March, the proposal valued Bovis at £1.2bn or 886p or a 7% premium to the previous trading day’s closing price.
Redrow has proposed £1.25 in cash and 1.32 new Redrow shares in exchange for each Bovis share, in addition to 30p dividend. This represented 814p per Bovis share based on Redrow’s share price of 499p or in other words a slight discount of 2%.
Talks with Galliford are ongoing and Redrow still holds out hope of reviving a deal but we think it would be risky to hold out for a hefty premium.
Separate from the M&A situation, Bovis has a significant job on its hands to rectify the problems which led to two profit warnings around the turn of the year, the departure of chief executive David Ritchie in January, and a £7m compensation payment to customers for defects in their new homes. (TS)
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Big News
Editor's View
Funds
Great Ideas
Great Ideas Update
Investment Trusts
Larger Companies
Main Feature
Smaller Companies
Story In Numbers
- AIM Stocks Ranking
- UK Pharma & Biotech Stocks
- Esure escapes Ogden damage
- 3-month low: Oil slips as US activity ramps up
- 7.9%: Investment trust’s big bet on Sports Direct
- 76%: Percentage of money going into European tech firms by US and Asian investors
- 25%: Ramsdens on the rise
- 500 tonnes: Morrisons is in good shape